Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neoplasms 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Scleroderma, Localized 1Radiation Injuries 1Prostatic Neoplasms 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia 1Neurodermatitis 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lichen Planus 1Leukemia, Hairy Cell 1Leukemia 1Keratoacanthoma 1Keloid 1Hemangioma 1Head and Neck Neoplasms 1Granuloma Annulare 1Dermoid Cyst 1Dendritic Cell Sarcoma, Interdigitating 1Cicatrix, Hypertrophic 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × Adrenal Cortex Hormones × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡